210 related articles for article (PubMed ID: 37415845)
1. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Ding X; Hua YJ; Zou X; Chen XZ; Zhang XM; Xu B; Ouyang YF; Tu ZW; Li HF; Duan CY; Zhang WJ; You R; Liu YP; Liu YL; Yang Q; Huang PY; Wang SN; Fan J; Chen MY
EClinicalMedicine; 2023 Jul; 61():102043. PubMed ID: 37415845
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Qu YY; Sun Z; Han W; Zou Q; Xing N; Luo H; Zhang X; He C; Bian XJ; Cai J; Chen C; Wang Q; Ye DW
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35537782
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S; Wang X; Han BH; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38388167
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
7. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
Mo Y; Pan Y; Zhang B; Zhang J; Su Y; Liu Z; Luo M; Qin G; Kong X; Zhang R; Pan Y; Liang Y; Wang D; Wei Y; Chen H; Jiang W
Front Immunol; 2023; 14():1298418. PubMed ID: 38239359
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Ding X; Zhang WJ; You R; Zou X; Wang ZQ; Ouyang YF; Peng L; Liu YP; Duan CY; Yang Q; Lin C; Xie YL; Chen SY; Liu YL; Gu CM; Xie RQ; Huang PY; Hong MH; Hua YJ; Chen MY
J Clin Oncol; 2023 May; 41(14):2571-2582. PubMed ID: 36735896
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study.
Lu N; Jiang YF; Xia WX; Huang Y; Xie CM; Xu C; Ye YF; Liu GY; Bei WX; Ke LR; Li WZ; Zhang C; Wang X; Liu Q; Chen X; Chen ZX; Xie C; Liang H; Xiang YQ
EClinicalMedicine; 2023 Aug; 62():102136. PubMed ID: 37593221
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.
Xia L; Zhou Q; Gao Y; Hu W; Lou G; Sun H; Zhu J; Shu J; Zhou X; Sun R; Wu X
Nat Commun; 2022 Dec; 13(1):7581. PubMed ID: 36481736
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Qu YY; Zhang HL; Guo H; Luo H; Zou Q; Xing N; Xia S; Sun Z; Zhang X; He C; Cai J; Zhang X; Wang Q; Ye DW
Clin Cancer Res; 2021 Nov; 27(21):5838-5846. PubMed ID: 34400414
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
17. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L; Jia GD; Lv XF; Xie SY; Guo SS; Lin DF; Liu LT; Luo DH; Li YF; Deng SW; Guo L; Zeng MS; Cai XY; Liu SL; Sun XS; Li XY; Li SC; Chen QY; Tang LQ; Mai HQ
Nat Commun; 2023 Aug; 14(1):4893. PubMed ID: 37580352
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
